Tykerb gets expanded US approval for breast cancer
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's Tykerb (lapatinib) has been granted accelerated approval by the US FDA to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women in combination with the hormonal therapy Femara (Novartis's letrozole).